The Australian | 30 November 2023
LTR Pharma has been featured in The Australian, for our innovative breakthrough in men’s health – erectile dysfunction nasal spray, Spontan. In the article, non-exective director Dr. Julian Chick highlights the essence of Spontan, emphasising its simple proposition – speed and spontaneity. “As the name suggests, the main factor is this is a product that […]
Perth Now | 18 November 2023
Australian Associated Press journalist Derek Rose has shared LTR Pharma’s story following the launch of our IPO last week. Of the Company’s commercialisation plans, he wrote: “Because the drug is already approved in a different form, LTR should have an easier time bringing SPONTAN® to market than companies seeking approval of an all-new medicine…SPONTAN® could […]
Biotech Daily | 17 Nov 2023
LTR Pharma has been featured in Biotech Daily. The article discusses the potential for the Company to disrupt the Erectile Dysfunction (ED) market with its commercialisation plans for intra-nasal product, SPONTAN®. The article also showcases the expertise of the team at LTR Pharma, writing: “The company said its Mr Rodne was the former chief executive […]
VIDEO | Lee Rodne speaks to OnMarket
LTR Pharma Executive Chairman, Lee Rodne, speaks to OnMarket about the Company’s Initial Public Offer (IPO) for a proposed listing on the Australian Securities Exchange (ASX) under ticker code $LTP, and commercialisation plans for SPONTAN®, an innovative intranasal spray treatment for Erectile Dysfunction (ED).
Media Release 29 March 2023
Australian Innovators Pursue $3.6Bn Erectile Dysfunction (ED) Market Brisbane-based LTR Pharma has today secured Ethics Approval for a bio-equivalence1 clinical study of its intranasal spray for erectile dysfunction (ED), ‘SPONTAN™’ – a crucial step in fast-tracking approval for this world-first product with the U.S. Food and Drug Administration (FDA). SPONTAN’s unique delivery technology (‘Intranasal’) bypasses […]